Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source

RG Hart; M Sharma; H Mundl; SE Kasner; SI Bangdiwala; SD Berkowitz; B Swaminathan; P Lavados; Y Wang; Y Wang; A Davalos; N Shamalov; R Mikulik; L Cunha; A Lindgren; A Arauz; W Lang; A Czlonkowska; J Eckstein; RJ Gagliardi; P Amarenco; SF Ameriso; T Tatlisumak; R Veltkamp; GJ Hankey; D Toni; D Bereczki; S Uchiyama; G Ntaios; B-W Yoon; R Brouns; M Endres; KW Muir; N Bornstein; S Ozturk; MJ O'Donnell; MM De Vries Basson; G Pare; C Pater; B Kirsch; P Sheridan; G Peters; JI Weitz; WF Peacock; A Shoamanesh; OR Benavente; C Joyner; E Themeles; SJ Connolly

Journal article

Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source

RG Hart, M Sharma, H Mundl, SE Kasner, SI Bangdiwala, SD Berkowitz, B Swaminathan, P Lavados, Y Wang, Y Wang, A Davalos, N Shamalov, R Mikulik, L Cunha, A Lindgren, A Arauz, W Lang, A Czlonkowska, J Eckstein, RJ Gagliardi Show all

NEW ENGLAND JOURNAL OF MEDICINE | MASSACHUSETTS MEDICAL SOC | Published : 2018

DOI: 10.1056/NEJMoa1802686

Abstract

BACKGROUND: Embolic strokes of undetermined source represent 20% of ischemic strokes and are associated with a high rate of recurrence. Anticoagulant treatment with rivaroxaban, an oral factor Xa inhibitor, may result in a lower risk of recurrent stroke than aspirin. METHODS: We compared the efficacy and safety of rivaroxaban (at a daily dose of 15 mg) with aspirin (at a daily dose of 100 mg) for the prevention of recurrent stroke in patients with recent ischemic stroke that was presumed to be from cerebral embolism but without arterial stenosis, lacune, or an identified cardioembolic source. The primary efficacy outcome was the first recurrence of ischemic or hemorrhagic stroke or systemic ..

View full abstract